Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

21.5%

39 terminated/withdrawn out of 181 trials

Success Rate

74.0%

-12.5% vs industry average

Late-Stage Pipeline

26%

47 trials in Phase 3/4

Results Transparency

53%

59 of 111 completed trials have results

Key Signals

9 recruiting59 with results30 terminated9 withdrawn

Enrollment Performance

Analytics

Phase 1

63(38.7%)

Phase 3

45(27.6%)

Phase 2

39(23.9%)

N/A

13(8.0%)

Phase 4

2(1.2%)

Early Phase 1

1(0.6%)

163Total

Phase 1(63)

Phase 3(45)

Phase 2(39)

N/A(13)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (181)

Showing 20 of 181 trials

NCT07556159Recruiting

A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

Role: collaborator

NCT06256731Completed

ETNA-MS Device Validation Study

Role: collaborator

NCT03156790Phase 2Terminated

PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia

Role: collaborator

NCT07497503Phase 1Not Yet Recruiting

A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants

Role: lead

NCT05579548Recruiting

A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding

Role: collaborator

NCT04020016Phase 1Completed

Study of Nalbuphine ER in Participants With Hepatic Impairment

Role: collaborator

NCT04838301Phase 2Recruiting

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Role: collaborator

NCT05385952Not ApplicableCompleted

GATT-Patch Versus TachoSil in Liver Surgery

Role: collaborator

NCT06780254Phase 1Completed

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of Single- and Multiple-Ascending Doses of MH-001 in Healthy Volunteers

Role: collaborator

NCT07413367Phase 1Active Not Recruiting

A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants

Role: collaborator

NCT02947685Phase 3Active Not Recruiting

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Role: collaborator

NCT05721573Phase 2Completed

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Role: collaborator

NCT02349906Phase 2Completed

Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases

Role: collaborator

NCT07222813Not ApplicableNot Yet Recruiting

Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP)

Role: collaborator

NCT05817812Phase 3Active Not Recruiting

A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

Role: collaborator

NCT06699836Phase 2Recruiting

A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC

Role: collaborator

NCT01522183Recruiting

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Role: collaborator

NCT04204252Phase 3Recruiting

Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"

Role: collaborator

NCT05155254Phase 3Active Not Recruiting

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Role: collaborator

NCT03633799Phase 3Active Not Recruiting

Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS

Role: collaborator